ArteraAI

Every H&E slide contains the integrated story of a tumor's biology. #ClinicalValidation is what turns that story into something a clinician can trust. Over the past several years, that's exactly what's happened: Artera's multimodal AI has been tested against real clinical outcomes, in randomized trials, and published in leading peer-reviewed journals. Swipe through to see our published data. #DigitalPathology #ProstateCancer

Progress in breast cancer care is made possible by countless researchers, clinicians, patients, and advocates working toward a common goal. We're proud to work with research luminaries like Eric Winer, MD, FASCO in our shared mission to advance our scientific understanding and improve patient outcomes. On World Breast Cancer Research Day, we recognize everyone whose dedication continues to advance our understanding of breast cancer and improve care for patients around the world. #WBCRD #BreastCancer #ArteraAI

Next stop: The Lumea 2026 DDX Summit. The Artera team is looking forward to joining leaders across digital pathology, diagnostics, and oncology to explore how innovation can drive meaningful impact for patients. Looking forward to a few days of collaboration, learning, and conversations about the future of AI-powered precision medicine. #DigitalPathology #ArteraOnTheGo

We're growing our leadership team! Artera is hiring a #ChiefMedicalOfficer to help shape the future of AI-powered precision medicine and guide the clinical strategy behind our next phase of growth. If you're passionate about advancing cancer care through innovation, clinical excellence, and collaboration, we'd love to hear from you. Learn more about the role: https://buff.ly/24wOzwY

The next generation of cancer biology assessment is here. Tissue morphology captures the complete story of tumor biology. Every routine H&E slide contains the integrated results of all biological pathways: genomic, transcriptomic, proteomic, epigenetic, immunologic, and microenvironmental. Artera's multimodal AI unlocks this comprehensive view, transforming routine pathology into precise risk assessment and personalized therapeutic guidance. See the full story in every slide. Read our new blog post to learn more → https://buff.ly/iaAwFOX #ProstateCancer #PrecisionMedicine #DigitalPathology #AIinHealthcare

Treatment decisions for intermediate-risk prostate cancer aren't always straightforward. In this five-part Urology Times video series, Dr. Amar Kishan discuss how AI-based biomarkers are helping inform decisions around ADT and advancing a more personalized approach to prostate cancer care. Watch the full series: https://buff.ly/CbIG0eh #ProstateCancer #PrecisionMedicine #RadiationOncology #AIinHealthcare #ArteraAI

Looking forward to another opportunity to connect with the urology community. The Artera team will be attending the 2026 Department of Urology Visiting Professor Event hosted by Atrium Health and engaging in conversations around the latest advances in prostate cancer care and precision medicine. #ArteraOnTheGo #ProstateCancer #PrecisionMedicine

How can AI help improve access to precision oncology? In this AJMC - The American Journal of Managed Care interview, Dr. Nancy Lin explores the role of multimodal AI in #breastcancer care, from faster risk stratification and streamlined workflows to the importance of robust clinical validation and equitable access. Hear the full conversation: https://buff.ly/190133R #PrecisionMedicine #AIinHealthcare #HealthEquity #ArteraAI

Genomic classifiers and digital pathology AI measure tumor biology at different scales. Genomic classifiers assess a pre-specified panel of genes: a single molecular layer that captures RNA expression patterns. This provides valuable insights but represents a limited view of tumor complexity. Artera's multimodal AI analyzes routine H&E slides and clinical information, which contain the integrated results of all biological pathways: → Genomic alterations → Transcriptomic programs → Proteomic function → Epigenetic regulation → Immune context → Microenvironmental interactions Tissue morphology is the visible manifestation of how all these biological layers work together to drive tumor behavior. Both approaches provide value. The difference is scope: one molecular layer versus the integrated expression of all biological events. Read our new blog post to learn more → https://buff.ly/SbwxaoY #PrecisionOncology #DigitalPathology

How can AI become part of routine clinical practice? In a recent interview with OncLive, Dr. Gerhardt Attard discusses the potential of multimodal AI to support more personalized treatment decisions in prostate cancer and why implementation may be more accessible than many realize. Because the #ArteraAI Prostate Test leverages routine pathology slides and standard clinical data, it has the potential to integrate into existing clinical workflows without requiring additional tissue or specialized technology. Read more: https://buff.ly/S6EVTNj #ProstateCancer #AIinHealthcare #PrecisionMedicine